Safety and efficacy of lithium in children and adolescents: A systematic review in bipolar illness
- Forfatter(e)
- Amerio, A. Ossola, P. Scagnelli, F. Odone, A. Allinovi, M. Cavalli, A. Iacopelli, J. Tonna, M. Marchesi, C. Ghaemi, S. N.
- År
- 2018
- Tidsskrift
- European Psychiatry
- Sider
- 85-97
- Kategori(er)
- Bipolare lidelser
- Tiltakstype(r)
- Antipsykotika
- Abstract
Introduction: Many clinicians are reluctant to use traditional mood-stabilizing agents, especially lithium, in children and adolescents. This review examined the evidence for lithium's safety and efficacy in this population.
Methods: A systematic review was conducted on the use of lithium in children and adolescents with bipolar disorder (BD). Relevant papers published through June 30th: 2018 were identified searching the electronic databases MEDLINE, Embase, PsycINFO and the Cochrane Library.
Results: 30 articles met inclusion criteria, including 12 randomized controlled trials (RCTs). Findings from RCTs demonstrate efficacy for acute mania in up to 50% of patients, and evidence of long-term maintenance efficacy. Lithium was generally safe, at least in the short term, with most common side effects being gastrointestinal, polyuria, or headache. Only a minority of patients experienced hypothyroidism. No cases of acute kidney injury or chronic kidney disease were reported.
Conclusions: Though the available literature is mostly short-term, there is evidence that lithium monotherapy is reasonably safe and effective in children and adolescents, specifically for acute mania and for prevention of mood episodes.
Copyright © 2018 Elsevier Masson SAS